Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
July 11, 2025 16:30 ET Â | Source: Ultragenyx Pharmaceutical Inc. Complete Response…
RAEOA and CMC Ignite a New Chapter: Oecusse to Lead Timor-Lestes Modernization
OECUSSE, Timor-Leste--(BUSINESS WIRE)--Â In a landmark display of visionary public-private collaboration, the…
